Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CV2CoV · 1 trial · 2 indications
An AESI (serious or nonserious) is defined as an AE or SAE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor could be appropriate.
An SAE is defined as any event that: • Results in death • Is immediately life-threatening • Requires inpatient hospitalization or prolongation of existing hospitalization • Results in persistent or significant disability/incapacity • Is a congenital anomaly/birth defect • Is a spontaneous miscarriage Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered SAEs when, based upon appropriate medical judgment, they may jeopardize the participant or may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.
An MAAE is defined as an AE that results in a visit to a medical professional. Medically attended visits are defined as a telemedicine visit, physician's office visit, urgent care visit, emergency room visit, hospitalization, or death.
Assessed solicited local reactions were injection site pain, redness, swelling, and lymphadenopathy.
Assessed solicited systemic reactions were fever, headache, fatigue, myalgia, arthralgia, and chills.
An unsolicited AE is defined as any AE that is volunteered from the participant and occurs within 28 days after vaccination.
| Arm | Type | Description |
|---|---|---|
| CV2CoV Dose Cohort 1 (Group 1a 2μg) | EXPERIMENTAL | Participants received 2 μg CV2CoV intramuscularly. |
| CV2CoV Dose Cohort 1 (Group 1b 4μg) | EXPERIMENTAL | Participants received 4 μg CV2CoV intramuscularly. |
| CV2CoV Dose Cohort 2 (8 μg) | EXPERIMENTAL | Participants received 8 μg CV2CoV intramuscularly. |
| CV2CoV Dose Cohort 3 (12 μg) | EXPERIMENTAL | Participants received 12 μg CV2CoV intramuscularly. |
| CV2CoV Dose Cohort 4 (16 μg) | EXPERIMENTAL | Participants received 16 μg CV2CoV intramuscularly. |
| CV2CoV Dose Cohort 5 (20 μg) | EXPERIMENTAL | Participants were scheduled to receive 20 μg CV2CoV Intramuscularly, but there were no participants enrolled in this group, and hence, there was no vaccine administered in this study group. |
| Name | Type | Description |
|---|---|---|
| CV2CoV (2 µg) | BIOLOGICAL | Study vaccine was administered as a single intramuscular injection. |
| CV2CoV (4 µg) | BIOLOGICAL | Study vaccine was administered as a single intramuscular injection. |
| CV2CoV (8 µg) | BIOLOGICAL | Study vaccine was administered as a single intramuscular injection. |
| CV2CoV (12 µg) | BIOLOGICAL | Study vaccine was administered as a single intramuscular injection. |
| CV2CoV (16 µg) | BIOLOGICAL | Study vaccine was administered as a single intramuscular injection. |
| CV2CoV (20 µg) | BIOLOGICAL | Study vaccine was planned to be administered intramuscularly. No vaccine was administered in the CV2CoV (20 µg) Group, since there were no participants enrolled in it. |
Inclusion Criteria: 1. Must provide documented informed consent prior to any study procedures being performed. 2. Is capable of understanding and agrees to comply with planned study procedures and to be available for all study visits, including being willing and able to use electronic devices durin...
CV2CoV is an investigational messenger RNA (mRNA) vaccine being developed for the prevention of COVID-19, caused by the SARS-CoV-2 virus. It is designed for use in adult participants who are already seropositive, meaning they have prior evidence of SARS-CoV-2 infection or vaccination.
CV2CoV is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical research on this mRNA vaccine candidate for COVID-19.
CV2CoV is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. A Phase 1 trial has been completed, but the vaccine remains in early-stage clinical testing and is not yet available commercially.
CV2CoV has been studied in one completed Phase 1 clinical trial, registered as NCT05260437. This trial assessed the safety, reactogenicity, and immunogenicity of the CV2CoV mRNA vaccine against SARS-CoV-2 in seropositive adult participants in the United States. The trial enrolled 99 participants.
Yes, CV2CoV is an mRNA vaccine. It is designed to deliver messenger RNA that encodes a SARS-CoV-2 antigen, prompting the immune system to produce a protective response against the virus. The completed Phase 1 trial evaluated its safety and immunogenicity in adults.